AMPH

Company Overview — What Does Amphastar Pharmaceuticals, Inc. Do?

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Amphastar Pharmaceuticals, Inc. (AMPH) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Yong F. Zhang and employs approximately 1,620 people, headquartered in RANCHO CU, California. With a market capitalization of $918M, AMPH is one of the notable companies in the Healthcare sector.

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Rating — Reduce (April 2026)

As of April 2026, Amphastar Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 48.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AMPH ranks #2,922 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Amphastar Pharmaceuticals, Inc. ranks #414 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AMPH Stock Price and 52-Week Range

Amphastar Pharmaceuticals, Inc. (AMPH) currently trades at $20.37. The stock lost $0.50 (2.4%) in the most recent trading session. The 52-week high for AMPH is $31.26, which means the stock is currently trading -34.8% from its annual peak. The 52-week low is $17.03, putting the stock 19.6% above its annual trough. Recent trading volume was 354K shares, suggesting relatively thin trading activity.

Is AMPH Overvalued or Undervalued? — Valuation Analysis

Amphastar Pharmaceuticals, Inc. (AMPH) carries a value factor score of 77/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 8.18x, compared to the Healthcare sector average of 23.63x — a discount of 65%. The price-to-book ratio stands at 1.18x, versus the sector average of 2.75x. The price-to-sales ratio is 1.28x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, AMPH trades at 5.77x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, Amphastar Pharmaceuticals, Inc. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

Amphastar Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Amphastar Pharmaceuticals, Inc. (AMPH) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 14.5%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 7.0% versus the sector average of -33.1%.

On a margin basis, Amphastar Pharmaceuticals, Inc. reports gross margins of 51.1%, compared to 71.5% for the sector. The operating margin is 22.3% (sector: -66.1%). Net profit margin stands at 15.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 5.2% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

AMPH Debt, Balance Sheet, and Financial Health

Amphastar Pharmaceuticals, Inc. has a debt-to-equity ratio of 107.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 4.02x, indicating strong short-term liquidity. Total debt on the balance sheet is $610M. Cash and equivalents stand at $216M.

AMPH has a beta of 0.76, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Amphastar Pharmaceuticals, Inc. is 56/100, reflecting average volatility within the normal range for its sector.

Amphastar Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Amphastar Pharmaceuticals, Inc. reported revenue of $728M and earnings per share (EPS) of $2.10. Net income for the quarter was $114M. Gross margin was 51.1%. Operating income came in at $162M.

In FY 2025, Amphastar Pharmaceuticals, Inc. reported revenue of $720M and earnings per share (EPS) of $2.10. Net income for the quarter was $98M. Gross margin was 49.5%. Revenue grew -1.7% year-over-year compared to FY 2024. Operating income came in at $140M.

In Q3 2025, Amphastar Pharmaceuticals, Inc. reported revenue of $192M and earnings per share (EPS) of $0.38. Net income for the quarter was $17M. Gross margin was 51.4%. Revenue grew 0.3% year-over-year compared to Q3 2024. Operating income came in at $25M.

In Q2 2025, Amphastar Pharmaceuticals, Inc. reported revenue of $174M and earnings per share (EPS) of $0.66. Net income for the quarter was $31M. Gross margin was 49.6%. Revenue grew -4.4% year-over-year compared to Q2 2024. Operating income came in at $42M.

Over the past 8 quarters, Amphastar Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $182M to $728M. Investors analyzing AMPH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AMPH Dividend Yield and Income Analysis

Amphastar Pharmaceuticals, Inc. (AMPH) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AMPH Momentum and Technical Analysis Profile

Amphastar Pharmaceuticals, Inc. (AMPH) has a momentum factor score of 29/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 31/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

AMPH vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Amphastar Pharmaceuticals, Inc. (AMPH) ranks #414 out of 838 stocks based on the Blank Capital composite score. This places AMPH in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AMPH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AMPH vs S&P 500 (SPY) comparison to assess how Amphastar Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

AMPH Next Earnings Date

No upcoming earnings date has been announced for Amphastar Pharmaceuticals, Inc. (AMPH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AMPH? — Investment Thesis Summary

The quantitative profile for Amphastar Pharmaceuticals, Inc. suggests caution. The value score of 77/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 29/100, a headwind for near-term performance.

In summary, Amphastar Pharmaceuticals, Inc. (AMPH) earns a Reduce rating with a composite score of 48.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AMPH stock.

Related Resources for AMPH Investors

Explore more research and tools: AMPH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AMPH head-to-head with peers: AMPH vs AZN, AMPH vs SLGL, AMPH vs VMD.